FDA approves Tryngolza (olezarsen) for familial chylomicronemia syndrome

Ionis Pharmaceuticals/Olezarsen (Tryngolza)

The FDA approved Tryngolza, the first antisense oligonucleotide approved for a lipid disorder. The approval was based on the Balance Phase 3 trial, which showed 42.5% triglyceride reduction at six months and 57% at one year in familial chylomicronemia syndrome, a rare genetic lipid condition.